| (Values in U.S. Thousands) | Dec, 2015 | Dec, 2014 | Dec, 2013 | Dec, 2012 | Dec, 2011 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -34,070 | -30,880 | -5,530 | -5,860 | -2,030 |
| Net Income Growth | -10.33% | -458.41% | +5.63% | -188.67% | +60.12% |
Tapimmune Inc (TPIVD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
TapImmune Inc. is an immunotherapy company. It specializes in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease. The Company also develops therapies for infectious diseases, autoimmune disorders, and transplant tissue rejection. It is involved in the development of HER2/neu for the treatment of breast cancer; and Folate Receptor Alpha, for the treatment of breast and ovarian cancer. TapImmune Inc. is based in Seattle, Washington.